G-CSF in the Treatment of Toxic Epidermal Necrolysis

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.

Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at admission and will be followed until 3 months after discharge.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of Liege; University of Liege
• Treatments: Sargramostim

Criteria

Inclusion Criteria:

• Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission

Exclusion Criteria:

• Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission

• Hypercoagulable state

• Cardiac or peripheral arterial disease

• Active malignancy

• Myelodysplastic syndrome or hematological malignancy

• Fructose intolerance

• Pregnancy

• Patient refusal